Physician profile
Michael N Plundo
NPI 1932366945
$151,484.68
in general payments reported to CMS, 2019-2025
61 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $36K · 2021: $28K · 2022: $26K · 2023: $10K · 2024: $9,102 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $7,837 · Travel and Lodging: $1,483 · Education: $52.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,529.68 |
| Food and Beverage | $7,837.08 |
| Travel and Lodging | $1,483.09 |
| Education | $52.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $80,757.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $34,603.33 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $24,465.84 | 2019-2023 | Xarelto |
| Abbvie INC. | $2,246.31 | 2020-2025 | |
| Lilly USA, LLC | $1,009.77 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $895.27 | 2019-2025 | Repatha, Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $538.58 | 2022-2025 | Eliquis |
| Pfizer INC. | $515.06 | 2019-2025 | |
| Valeritas, INC. | $411.80 | 2019 | |
| Glaxosmithkline, LLC. | $364.75 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Mannkind Corporation | $326.72 | 2022-2024 | Afrezza, V-Go |
| Biohaven Pharmaceutical Holding Company Ltd. | $305.62 | 2022 | |
| Amarin Pharma, INC. | $282.10 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $276.16 | 2019-2024 | |
| Exact Sciences Corporation | $274.65 | 2023-2025 | Cologuard Collection Kit |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Plundo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.